Azenta Q2 revenue $145M, GAAP EPS -$3.41; cuts FY2026 guidance, extends long-range plan to 2029

Azenta, Inc.

2026-Q2 EPS reported -$3.83 revenue$293,437,000

Organic revenue declined 3% YoY; $149M non-cash goodwill impairment on Multiomics unit.
FY2026 organic growth guidance cut to -2% to +1% (prev. 3-5%); Adj. EBITDA margin now -125bps to flat.
Long-range plan extended from 2028 to 2029; B Medical Systems sale delayed due to buyer financing.
Non-GAAP diluted EPS -$0.04 vs. +$0.01 prior year; cash and securities $565M; no share repurchases yet.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Azenta, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $145 million, EPS ($3.41). Guidance lowered.

Period: the fiscal quarter ended March 31, 2026
Revenue: $145 million
EPS: ($3.41)
Guidance: lowered
Result: reported results

Exact text from the filing

position Azenta for improved execution, greater consistency, and profitable long‐term value creation.” Second Quarter Fiscal 2026 Results - Continuing Operations • Revenue was $145 million, up 1% year over year. Organic revenue, which excludes a 3-percentage point impact from foreign exchange and a 1-percentage point from the acquisition of UK Biocentre Limited,

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Azenta, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-030677

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.